BP emergency in pregnancy 🤰
One tool with three tabs: the severe BP emergency, hypertension and pre-eclampsia (classification and delivery), and antihypertensives and magnesium sulphate. An emergency algorithm for severe hypertension in pregnancy, labour and up to 6 weeks postpartum. Two readings 15 min apart confirm acute-onset severe hypertension (≥ 160 and/or ≥ 110 mmHg), which is treated within 30–60 min. The disorder is classified from the BP, platelets, liver enzymes, creatinine and symptoms (ISSHP 2021 and ACOG severe features: chronic or gestational hypertension, pre-eclampsia with or without severe features, HELLP, eclampsia). The first drug is chosen from IV access, asthma, heart block, bradycardia or heart failure (no labetalol) and maternal tachycardia (no hydralazine first), then the ACOG Committee Opinion 767 order set is shown dose by dose with the BP checks between doses. Magnesium sulphate is marked as treatment (eclampsia), indicated (pre-eclampsia with severe features, HELLP, severe gestational hypertension), to consider, not indicated, or contraindicated (myasthenia gravis), with the IV (Zuspan) and IM (Pritchard) regimens, the maintenance pump rate from the bag, dose reduction in kidney impairment, monitoring, toxic levels and calcium gluconate. Below: IV infusions for refractory hypertension (labetalol, nicardipine, hydralazine, nitroglycerin for pulmonary oedema; nitroprusside only as a last resort), oral drugs after control (methyldopa, labetalol, nifedipine) and drugs to avoid, timing of delivery by gestation, and postpartum care with breastfeeding-compatible drugs. ESC 2025 thresholds and targets sit beside ACOG, ISSHP and NICE. The Hypertension and pre-eclampsia tab classifies the disorder from the gestation, BP, labs and clinical and fetal findings and gives oral treatment from 140/90, low-dose aspirin for prevention, the timing and mode of delivery by gestation (37 weeks without severe features, 34 weeks with them, any gestation after stabilisation for eclampsia, HELLP or deterioration), postpartum follow-up and the lifelong cardiovascular risk. The Antihypertensives and MgSO₄ tab lists the oral drugs with doses (methyldopa (Aldomet), labetalol, extended-release nifedipine, then hydralazine, metoprolol, amlodipine and thiazides), the drugs to avoid (ACE inhibitors, ARBs, sacubitril/valsartan, atenolol, MRAs), the emergency order sets, magnesium regimens and breastfeeding choices.
- Pritchard IM regimen (no infusion pump)WHO 2011 · ACOG4 g IV over 5–20 min plus 10 g IM (5 g of 50% deep IM into each buttock, with 1 mL 2% lidocaine), then 5 g IM every 4 h into alternate buttocks for 24 h. Only if reflexes present, RR > 12/min and urine > 100 mL in 4 h.
- Recurrent seizure: a further 2 g (4 g if > 70 kg) IV over 5 minACOG 2020 · NICEPersistent seizures despite magnesium: midazolam or lorazepam, then airway support and brain imaging.
- Monitor hourly: patellar reflexes, respiratory rate > 12/min, SpO₂, urine > 25–30 mL/hACOG 2020Therapeutic level 4.8–8.4 mg/dL (2–3.5 mmol/L). Loss of reflexes > 9.6 mg/dL (> 4 mmol/L), respiratory depression > 12 mg/dL (> 5 mmol/L), cardiac arrest > 30 mg/dL. Levels only with kidney impairment or signs of toxicity.
- Toxicity: stop the infusion, calcium gluconate 10% 10 mL (1 g) IV over 10 minACOG 2020 · NICESupport ventilation; check the serum level.
- Do not give magnesium in myasthenia gravisIIIACOG 2020Can precipitate a myasthenic crisis.
- Caution with nifedipine and other calcium-channel blockersACOG CO 767Theoretical neuromuscular blockade and hypotension; usually used together safely with monitoring.
- Fetal neuroprotection before 32 weeksACOG CO 455Birth expected before 32 weeks: magnesium sulphate also reduces cerebral palsy (4 g load, 1 g/h).
- Labetalol infusion 1–2 mg/min (start 20 mg/h, double every 30 min to 160 mg/h)ACOG CO 767 · NICEAfter the IV bolus steps; continuous maternal ECG and fetal monitoring. Not in asthma, heart block or heart failure.
- Nicardipine 5 mg/h, increase by 2.5 mg/h every 5–15 min to 15 mg/hACOG CO 767Effective and well tolerated in pregnancy; reflex tachycardia, headache. Central line or large vein (phlebitis).
- Hydralazine infusion 0.5–10 mg/hNICE · RCOGAfter 5–10 mg IV boluses; watch for maternal hypotension and fetal distress. Give with a small fluid preload (≤ 500 mL) only if dry.
- Pulmonary oedema: nitroglycerin 5 µg/min, titrate every 3–5 min to 100 µg/min, with IV furosemideESC 2025The preferred drug when severe hypertension comes with pulmonary oedema.
- Avoid sodium nitroprusside except as a last resortESC 2025 · ACOGFetal cyanide toxicity after 4 h; only for refractory life-threatening hypertension, for the shortest time.
Pump rates in mL/h for labetalol, nicardipine, hydralazine and nitroglycerin: IV drug dosing.
- Methyldopa (Aldomet)First line250 mg 2–3 times daily; up to 3 g/day in 2–4 doses (ACOG 0.5–3 g/day)Central α2-agonist with the longest safety record, including child follow-up. Sedation, depression, raised liver enzymes, positive Coombs test. Slow onset (hours to days). Stop within 2 days after birth.
- LabetalolFirst line100 mg twice daily; up to 2400 mg/day in 2–4 doses (ACOG 200–2400 mg/day)α1/β-blocker. Avoid in asthma, heart block, bradycardia and decompensated heart failure. Monitor the newborn for bradycardia and hypoglycaemia.
- Nifedipine extended-releaseFirst line30–60 mg once daily, up to 120 mg/day (NICE modified-release 10–20 mg twice daily, up to 40 mg twice daily)Dihydropyridine CCB. Headache, flushing, ankle oedema, tachycardia. Do not use the immediate-release capsule for chronic treatment.
- Hydralazine (oral)Second line10–25 mg 3–4 times daily; up to 200–300 mg/dayAdd-on only: reflex tachycardia when used alone; lupus-like syndrome at high doses.
- MetoprololSecond line25–100 mg twice dailyAcceptable β1-blocker (ESC). Avoid atenolol: fetal growth restriction.
- AmlodipineSecond line5–10 mg once dailyLess pregnancy data than nifedipine; widely used postpartum.
- HydrochlorothiazideSecond line12.5–50 mg dailyCan be continued in chronic hypertension already on it (ACOG); avoid in pre-eclampsia (reduced plasma volume).
- Contraindicated: ACE inhibitors, ARBs, sacubitril/valsartan and direct renin inhibitorsIIIESC 2025Fetal renal failure, oligohydramnios, skull and lung hypoplasia in the 2nd and 3rd trimesters; switch before conception or as soon as pregnancy is confirmed.
- Avoid: atenololIIIESC 2025Fetal growth restriction.
- Avoid: spironolactone and other MRAsESC 2025Anti-androgenic effects on the male fetus (eplerenone has limited data).
- Avoid: sodium nitroprusside except as a last resortESC 2018 · ACOGFetal cyanide toxicity with infusions over 4 h.
- Do not give immediate-release nifedipine sublingually or chewedACOG CO 767Swallow whole; caution with magnesium sulphate (theoretical neuromuscular blockade and hypotension).
Full classification, aspirin prevention and follow-up are in the Hypertension and pre-eclampsia tab; every drug and the postpartum choices in Antihypertensives and MgSO₄.
- American College of Obstetricians and Gynecologists. Clinical management guidelines: Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. ACOG Committee Opinion No. 767. Obstet Gynecol 2019;133:e174-e180.
- American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia: ACOG Practice Bulletin No. 222. Obstet Gynecol 2020;135:e237-e260.
- Magee LA, Brown MA, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens 2022;27:148-169.
- National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. NICE guideline NG133, 2019 (updated 2023).
- De Backer J, Haugaa KH, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J 2025.
- McEvoy JW, McCarthy CP, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024;45:3912-4018.
- Tita AT, et al. Treatment for mild chronic hypertension during pregnancy (CHAP). N Engl J Med 2022;386:1781-1792.
- Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial. Lancet 2002;359:1877-1890.
- World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva: WHO, 2011.
- American College of Obstetricians and Gynecologists. Chronic hypertension in pregnancy. ACOG Practice Bulletin No. 203. Obstet Gynecol 2019;133:e26-e50.
- American College of Obstetricians and Gynecologists. Medically indicated late-preterm and early-term deliveries. ACOG Committee Opinion No. 831. Obstet Gynecol 2021;138:e35-e39.
- The Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995;345:1455-1463.